Related Experiment Video
Updated: Jun 2, 2026
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Partially hydrolyzed cow's milk formula has a therapeutic effect on the infants with mild to moderate atopic
Ying-Ying Jin1, Rui-Ming Cao, Ji Chen
1Department of Pediatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Insights
Partially hydrolyzed cow's milk formula (phCMF) effectively treated infants with mild to moderate atopic dermatitis (AD). This therapeutic approach improved AD severity and reduced flare-ups without impacting infant growth.
Area of Science:
- Pediatric Dermatology
- Clinical Nutrition
- Allergy Immunology
Background:
- Partially hydrolyzed cow's milk formula (phCMF) is known for allergy prevention in high-risk infants.
- The therapeutic use of phCMF for existing atopic dermatitis (AD) in infants has not been previously reported.
- Mild to moderate AD affects a significant number of infants, necessitating effective treatment options.
Purpose of the Study:
- To evaluate the therapeutic efficacy of phCMF in infants diagnosed with mild to moderate atopic dermatitis (AD).
- To compare the effects of phCMF versus conventional cow's milk formula (CMF) on AD severity and related biomarkers.
- To assess the impact of phCMF on infant growth and allergy profiles.
Main Methods:
- A double-blind clinical trial involving 113 infants under 6 months with AD.
- Infants were randomized to receive either phCMF or CMF for 12 weeks.
- AD severity was assessed using JDASS and SCORAD systems; allergy profiles (EOS, IgE, cytokines, Treg) and growth were monitored.
Main Results:
- The phCMF group showed significant reductions in AD severity scores at 4, 8, and 12 weeks compared to enrollment (p < 0.05).
- AD severity scores significantly decreased in the phCMF group compared to the CMF group after 12 weeks (p < 0.05).
- phCMF significantly reduced AD flare-ups (p = 0.002) and increased the Th1/Th2 ratio (p = 0.041) without affecting growth rates.
Conclusions:
- Partially hydrolyzed cow's milk formula (phCMF) demonstrates a novel therapeutic effect for mild to moderate infant atopic dermatitis.
- phCMF treatment led to significant clinical improvement in AD symptoms and reduced disease activity.
- The use of phCMF in infants with AD is safe and does not compromise nutritional status or growth.
Objective:
The allergy-preventing effect of partially hydrolyzed cow's milk formula (phCMF) in infants at high risk of atopic dermatitis (AD) has been demonstrated in many studies. However, the therapeutic potential of phCMF in treating the infants with AD has not been reported. We sought to assess such therapeutic efficacy of phCMF in infants with mild to moderate AD.
Methods:
From 2006 to 2008, 113 infants <6 months of age with AD were randomized to receive either partially hydrolyzed cow's milk formula (phCMF) or conventional cow's milk formula (CMF) in a double-blind clinical trial. Assessments were made at enrollment and at weeks 4, 8, and 12. The severity of AD was assessed using two scoring systems: Standard guideline for management (diagnosis, severity scoring, and therapy) of AD by the Japanese Dermatological Association Scoring System (JDASS) and the SCORing Atopic Dermatitis (SCORAD). Growth status of the infants was evaluated. Allergy profile was assessed by measuring total blood eosinophils (EOS), total/specific IgE, Th1/Th2 cytokine profiles, and the percentage of regulatory T cells.
Results:
After follow-up for 12 wk, 27 infants (23.89%) dropped off study. Analysis was performed on 86 infants by the end of 12-wk observation. The AD severity scores were significantly reduced in the phCMF group (n = 56) compared with CMF group (n = 30) after 12 wk (p < 0.05). The severity scores of phCMF group were significantly reduced at weeks 4, 8, and 12 compared to enrollment (p < 0.05). In contrast, no significant improvement was observed for CMF group at any of those time points (p > 0.05). The number of AD flare-ups was significantly decreased in the phCMF group (p = 0.002). Th1/Th2 ratio in phCMF was significantly increased compared with CMF group (p = 0.041). The growth rates did not differ significantly between these feeding groups at any assessed time point (p > 0.05) and were in the normal range.
Conclusion:
This study suggests a novel therapeutic effect of phCMF in treating infants with mild to moderate AD during the first 6 months of their life without affecting their nutritional status.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:30Development of Human Microbiota
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:27Acne Infection